Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBBNASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBBiShares Biotechnology ETF$130.02+0.4%$124.46$107.43▼$150.57$5.47B0.731.47 million shs658,990 shsREGNRegeneron Pharmaceuticals$545.00-0.5%$549.38$476.49▼$1,211.20$59.10B0.33905,431 shs456,413 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBBiShares Biotechnology ETF0.00%+2.81%+3.92%+10.98%-3.75%REGNRegeneron Pharmaceuticals0.00%+4.61%+12.39%-4.96%-46.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals4.946 of 5 stars4.45.01.72.32.71.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBBiShares Biotechnology ETF 2.67Moderate Buy$130.02N/AREGNRegeneron Pharmaceuticals 2.80Moderate Buy$813.5749.28% UpsideCurrent Analyst Ratings BreakdownLatest REGN and IBB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025REGNRegeneron PharmaceuticalsArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/9/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.006/5/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.006/2/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$700.00 ➝ $650.006/2/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.006/2/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.005/30/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$662.005/30/2025REGNRegeneron PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$700.00 ➝ $580.005/27/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$943.00 ➝ $662.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$14.20B4.14$45.49 per share11.98$268.50 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBBiShares Biotechnology ETFN/AN/A0.00∞N/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$4.41B$39.2813.8714.332.0031.94%15.27%11.93%8/1/2025 (Estimated)Latest REGN and IBB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025REGNRegeneron Pharmaceuticals$8.53N/AN/AN/A$3.30 billionN/A4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBBiShares Biotechnology ETF$0.380.29%N/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.65%N/A8.96%N/ALatest REGN and IBB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBBiShares Biotechnology ETFN/AN/AN/AREGNRegeneron Pharmaceuticals0.094.934.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBBiShares Biotechnology ETF62.45%REGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipIBBiShares Biotechnology ETFN/AREGNRegeneron Pharmaceuticals7.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBBiShares Biotechnology ETFN/A42.10 millionN/AOptionableREGNRegeneron Pharmaceuticals15,106107.96 million100.39 millionOptionableREGN and IBB HeadlinesRecent News About These CompaniesAugust 22nd Options Now Available For Regeneron Pharmaceuticals, Inc. (REGN) - NasdaqJuly 5 at 9:38 AM | nasdaq.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc.July 5 at 8:41 AM | marketbeat.com2 Beaten-Down Stocks to Buy and HoldJuly 5 at 7:45 AM | fool.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by IFM Investors Pty LtdJuly 5 at 6:28 AM | marketbeat.comPrincipal Financial Group Inc. Has $82.21 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 5 at 5:30 AM | marketbeat.comTeacher Retirement System of Texas Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 5 at 5:22 AM | marketbeat.comREGN - Regeneron Pharmaceuticals Inc Valuation - MorningstarJuly 4 at 12:06 PM | morningstar.comMRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by GF Fund Management CO. LTD.July 4 at 8:02 AM | marketbeat.comVontobel Holding Ltd. Has $4.66 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 4 at 4:44 AM | marketbeat.comRegeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M OpportunityJuly 3 at 4:02 PM | biospace.comBRegeneron’s Pozelimab Study: A New Hope for Rare Disease PatientsJuly 3 at 12:20 PM | tipranks.comFDA Grants Accelerated Approval to Regeneron's Blood Cancer DrugJuly 3 at 10:20 AM | zacks.comFirst Horizon Advisors Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)July 3 at 7:08 AM | marketbeat.comRegeneron wins FDA accelerated approval for Lynozyfic in MMJuly 3 at 6:46 AM | thepharmaletter.comTRegeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDAJuly 3 at 6:46 AM | msn.comRegeneron stock rises after FDA approval for blood cancer therapyJuly 2 at 3:44 PM | investing.comRegeneron Shares Climb Following FDA Approval of Blood Cancer TreatmentJuly 2 at 3:44 PM | msn.comRegeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock JumpsJuly 2 at 3:44 PM | msn.comRegeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer TreatmentJuly 2 at 11:45 AM | wsj.comUS FDA approves Regeneron's blood cancer therapyJuly 2 at 11:11 AM | reuters.comRegeneron Pharmaceuticals Receives FDA Accelerated Approval for Lynozyfic™ in Treating Relapsed or Refractory Multiple MyelomaJuly 2 at 11:11 AM | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN and IBB Company DescriptionsiShares Biotechnology ETF NASDAQ:IBB$130.02 +0.47 (+0.36%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$130.08 +0.06 (+0.05%) As of 07/3/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Regeneron Pharmaceuticals NASDAQ:REGN$545.00 -2.74 (-0.50%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$547.81 +2.81 (+0.52%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
